FDA headquarters in Washington DC.

JHVEPhoto/iStock Editorial via Getty Images

Capricor Therapeutics (CAPR) announced that its operating expenses are under review after the U.S. Food and Drug Administration on Friday declined to approve its cell therapy candidate Deramiocel for the second time in less than two years.

In a statement, the

Source link

Leave a Reply

Discover more from Occasional Digest

Subscribe now to keep reading and get access to the full archive.

Continue reading